Why Germany sits at the centre of EU medical-cannabis demand
Germany has the largest medical-cannabis patient population in Europe and the most mature regulatory framework. The German market is what most Thai exporters mean when they say "EU export" — the regulatory clarity, the licensed importer base, the patient demand, and the prescriber confidence are all furthest along here.
For a Thai cultivator considering EU supply, Germany is usually the entry point. The pathway is documented, the requirements are clear, and the demand is substantial. This piece walks through what a licensed German importer actually verifies before sourcing.
The German regulatory framework, briefly
Three pieces fit together:
1. Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) — the Federal Institute for Drugs and Medical Devices. Authorises medical-cannabis imports, supervises domestic manufacture, monitors the supply chain. Every licensed German importer holds a BfArM authorisation specific to their import activity.
2. The CanG reform of April 2024 — the Cannabis Act that re-classified cannabis from a narcotic (Betäubungsmittelgesetz / BtMG) to a regulated medicinal product. Practically, this removed the requirement for the special BtMG prescription form (Betäubungsmittelrezept), allowing standard prescriptions, while keeping the requirement that medical cannabis be dispensed only through licensed pharmacies (Apothekenpflicht). The reform expanded patient access without weakening supply-chain rigour.
3. EU-GMP — Good Manufacturing Practice as harmonised across the European Union. Imported medical cannabis must be processed under EU-GMP-equivalent conditions, with per-batch documentation that an EU-GMP auditor would recognise. For Thai exporters, this is the single most demanding piece of the German pathway.
What "EU-GMP-equivalent" actually requires
A cultivation site can be excellent without being EU-GMP-equivalent. The two standards overlap but are not the same thing:
| Property | TH-GACP | EU-GMP |
|---|---|---|
| Cultivation hygiene | Required | Implicit (covered upstream) |
| Documented SOPs | Required | Required, more granular |
| Personnel qualification | Required | Required, with specific training records |
| Environmental controls | Required for clean-rooms | Required across the entire post-harvest stage |
| Batch separation | Required | Required, with auditable records |
| Validation studies | Not explicitly required | Required (cleaning, sterilisation, packaging) |
| Quality unit | Implicit | Required as a distinct organisational function |
| Deviation handling | Implicit | Documented procedure required |
The practical implication: Thai cultivation sites need TH-GACP for the cultivation stage and either EU-GMP certification or a credible EU-GMP-equivalent declaration for the post-harvest stage (drying, curing, trim, packaging). Some Thai exporters work with EU-GMP-certified contract packagers in Thailand or in transit; others have built their own EU-GMP-equivalent processing facilities.
For a German importer, the verification is concrete: they will ask for the EU-GMP certificate or the equivalent declaration, the underlying audit report, and a sample batch documentation pack. They will read it carefully.
What licensed German importers verify before signing
In practice, the document pack a German importer asks for before contract signing includes:
Cultivation foundation
- TH-GACP certification with site identifier
- Department of Thai Traditional and Alternative Medicine licence numbers
- Cultivation site audit report (ideally third-party, recently conducted)
- Inputs disclosure: water testing, pesticide regime, fertiliser chemistry
Post-harvest manufacture (EU-GMP focus)
- EU-GMP certification or EU-GMP-equivalent declaration
- Quality manual, master batch records, deviation/CAPA procedures
- Validation studies for cleaning, sterilisation (if applicable), and packaging
- Personnel training records and quality-unit organisation
Per-batch quality
- ISO/IEC 17025-accredited Certificate of Analysis covering: full cannabinoid panel, full terpene panel (German prescribers often select on terpene profile), microbial limits per EU Pharmacopoeia, pesticide residues per EU MRL, heavy metals (Pb, Cd, As, Hg), mycotoxins, residual solvents (where relevant)
- Retained samples per batch for the labelled shelf life
- Method references per test
Logistics and chain-of-custody
- Export licence and CITES (if applicable)
- Cold-chain protocol with continuous logging
- Customs and border-control documentation pre-cleared with the importer
Pharmacovigilance readiness
- Procedure for adverse-event handling
- Batch traceability sufficient to identify all units shipped to a specific pharmacy if a recall is needed
- Direct compliance contact at the exporter
How the German prescription pathway actually works
The CanG reform simplified the prescriber's experience but didn't loosen the supply-chain expectations. Today:
- A German physician writes a standard prescription naming the specific medical-cannabis product and the indication.
- The patient takes the prescription to a licensed pharmacy (Apothekenpflicht — only pharmacies can dispense).
- The pharmacy orders the product from a licensed German importer (or holds stock).
- The importer's QA verifies the batch documentation upon receipt and dispenses to the pharmacy.
- The patient receives the medication with a dispensing label that ties it to the batch shipped.
This chain only works if the import-side documentation is complete. If a TGA-equivalent post-import audit identifies a gap — a missing CoA, an unrecorded environmental excursion, a strain identifier that doesn't match the BfArM registration — the pharmacy faces dispensing restrictions until the gap is closed.
What German prescribers care about (that Australian prescribers might not yet)
A subtle but important difference: German prescribers, particularly those in pain medicine and oncology-supportive care, frequently select cultivars on terpene profile, not just cannabinoid ratio. The clinical literature on terpene-driven response is more developed in German practice than in many other markets.
The practical implication for Thai exporters: a CoA that reports cannabinoids but only "total terpenes: 2.1%" without a per-terpene breakdown will face skepticism in Germany. A CoA that names myrcene, β-caryophyllene, limonene, linalool, α-pinene, humulene, and a handful of others with quantified percentages will be the baseline expectation.
This is one reason why our standard CoA panel is the full ISO/IEC 17025 set — it's what the most demanding regulated markets ask for.
Where the German market is heading
Three trends shape what BfArM-aligned supply will look like over the next 24 months:
Continued patient growth. The CanG reform expanded prescriber confidence. Patient counts have grown materially since 2024 and are projected to continue.
Pharmacist-led product selection. German pharmacies are becoming more sophisticated about cannabis. The pharmacist's professional knowledge increasingly influences which products move; supply discipline matters at this level too.
Cluster-of-trust dynamics. German importers tend to work with a small list of trusted exporters and resist switching. Earning a place on that list takes documentation, time, and consistent delivery against contract terms. Once on the list, the relationship is durable.
How CannaBless aligns to BfArM expectations
We supply licensed German importers because the regulatory pathway above describes the kind of supplier we want to be. Concretely:
- TH-GACP cultivation with documentation aligned to EU-GACP principles
- Post-harvest manufacture under EU-GMP-equivalent conditions, with ongoing work toward formal EU-GMP certification
- ISO/IEC 17025 CoA per batch with the full terpene panel German prescribers prefer
- Cold-chain protocol and continuous logging from packing through arrival
- A named compliance contact at the export desk for direct German importer queries
If you're a licensed German importer evaluating Thai supply, the documentation pack is what to ask for first. If we cannot produce it within a business week, we are not BfArM-ready. If we can, we likely are. Patients in Berlin, Hamburg, and Munich depend on the difference being real.